Bafna Pharmaceuticals Limited has informed the Exchange about the re-constitution of the Audit Committee, Nomination-Remuneration Committee of the Board w.e.f June 25, 2025
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bafna Pharmaceuticals has informed the stock exchanges that Mr. Palamadai Krishnan Sundaresan (DIN: 06954189) retired as an Independent Director on June 24, 2025, upon completing his first term. He also stepped down as Chairman of the Audit Committee and as a member of the Nomination & Remuneration Committee. Effective June 25, 2025, the Board reconstituted both committees: Mr. Navin Kumar now chairs the Audit Committee, and Mrs. Ravichandran Chitra chairs the Nomination & Remuneration Committee. The company confirmed that the Board and its committees continue to meet all applicable legal requirements.
This is a routine, planned change due to the completion of the independent director's first term, not a sudden or controversial exit. The company has already reconstituted its committees in compliance with regulations, so there should be no material impact on the stock price or shareholder interests.